Optimising Patient Recruitment
ICTU Global has developed a network of investigators in both primary and secondary care who have taken part in our studies over the last 10 years.
Strong engagement with the Chief Investigator and study team throughout the study and innovative recruitment strategies have contributed to ability to deliver target subject recruitment on time.
ICTU Global optimises patient recruitement through deep knowledge of patient groups and clinical services. We have national and international reach via clinical and academic networks with a Database of 800+ primary & secondary sites in Europe.
Our Recruitment Outcomes
Oncology trials:
|
Trial |
Population |
Geographical remit |
Recruitment |
|
IES |
Postmenopausal, ER+/ER unknown early breast cancer (adjuvant) |
UK, Argentina, Australia, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, France, Greece, Poland, Portugal, Serbia, Slovakia, Slovenia, Romania, Russia, Hong Kong, Hungary, Ireland, Spain, Italy, Israel, New Zealand, Malta, Norway, Germany, USA, Sweden, Switzerland, Netherlands, Peru, South Africa |
4724 patients randomised (on target) |
|
DEVA |
Postmenopausal, early breast cancer (adjuvant) |
UK, France, Malta, Netherlands, Spain |
803 patients randomized (on target) |
|
REACT |
Pre & post-menopausal, early breast cancer (adjuvant) |
UK and Germany |
2590 patients randomised (on target) |
|
Neocent (pilot) |
ER+early breast cancer (neoadjuvant) |
UK and Korea |
44 patients randomised (on target) |
Cardiovascular & Diabetes trials:
|
Trial |
Population |
Geographical remit |
Recruitment |
|
ASCOT |
Hypertensives with no history of CHD |
UK and Ireland |
9098 patients in 23 months (on target) |
|
PREMIUM |
Hypertensives with & without CVD & type 2 diabetes |
UK, Ireland, Netherlands |
3300 patients randomised in 12 months (300 > target) |
|
ADVANCE |
Type 2 diabetes with/without CVD |
UK, Ireland, Estonia, Lithuania, Russia |
2101 patients in 18 months (on target) |
|
UMPIRE |
Established CVD/ high estimated CV risk |
India, Netherlands, Ireland, England |
2004 patients randomised in 13 months (4 > target) |
|
FOURIER
|
High-risk CVD on stable statin therapy |
UK
|
782 patients in 18 months
|
|
DAVINCI |
Established CVD/ high estimated CV risk |
18 European Countries |
6000 patients recruited in 18 months (on target) |
Medical Device trials:
|
Trial |
Population |
Geographical remit |
Recruitment |
|
NESIC |
Intermittent Claudication / Peripheral Vascular Diseases |
UK |
188 patients in 24 months (on target) |
|
REI-EXCISE |
Breast Cancer |
UK |
143 in 10 months (82% of target) |
|
RYGB/GOP/VLCD |
Obesity |
UK |
18 patients randomised |
|
ENDOBARRIER |
Type 2 diabetes with BMI between 30-50kg/m2 |
UK |
160 patients in 23 months (on target) |